| January 5 |
Immutep Announces Positive Interim Results in Phase I/II Chemoimmunotherapy Trial in Breast Cancer |
| January 5 |
Merck Serono: Study Published in JCO Shows Erbitux Enhances Efficacy in mCRC Patients with KRAS Wild-Type Tumors in 1st-Line Setting |
| January 5 |
Discovery Labs' Surfaxin Phase 2 BPD Clinical Trial Results Published in Pediatrics |
| January 5 |
Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer |
| January 5 |
Inflammatory Factors May be Key to Controlling Diabetic Macular Edema |
| January 6 |
Kythera Biopharmaceuticals Announces Positive Results from Two Phase 2 Studies with ATX-101 Demonstrating Reduction of Submental Fat |
| January 6 |
Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice |
| January 6 |
Acacia Pharma Completes Clinical Trial with APD 405 for Nausea & Vomiting |
| January 6 |
Study Demonstrates that AHCC Enhances Immune System by Increasing the Production of Key Dendritic Cells |
| January 7 |
Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers |
| January 8 |
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients |
| January 8 |
Positive Results for Peplin's Phase IIb AK Trial |
| January 8 |
Syntarga Demonstrates In Vivo Proof of Concept for its Antibody-Drug Conjugate Technology |
| January 8 |
First Candidate from Scynexis' Novel Cyclophilin Inhibitor Platform, SCY-635, Establishes Proof of Concept in HCV-Infected Adults |
| January 8 |
Juvaris BioTherapeutics Announces Positive Data from Clinical Trial of JVRS-100 Adjuvanted Flu Vaccine |
| January 8 |
Altus Pharmaceuticals Successfully Completes Phase 1 Study of Long Acting Formulation of Recombinant Human Growth Hormone |
| January 8 |
Why Bladder Cancer Is Deadlier for Some |
| January 9 |
Study Finds More Effective Treatment for Pneumonia Following Influenza |
| January 9 |
Orexigen Therapeutics Announces First of Four Phase 3 Trials of Contrave Meets Co-Primary and Key Secondary Endpoints |
| January 9 |
RegeneRx Reports Phase II Pressure Ulcer Trial Results |
| January 9 |
Gene Abnormality Found to Predict Childhood Leukemia Relapse |
| January 9 |
New Malaria Drug May Meet Resistance Says Expert |
| January 12 |
ARYx Therapeutics, Inc. Provides Additional Data on Atrial Fibrillation Clinical Trial on ATI-2042 |
| January 12 |
InterMune Reports Results from Triple Combination Study of ITMN-191 |
| January 12 |
Repros Therapeutics Inc. Announces That Proellex Significantly Reduced Pain in a U.S. Phase 2 Clinical Trial in Women with Moderate to Severe Endometriosis |
| January 12 |
Qnexa Treatment Results in Improved Glucose Control in Obese Non-Diabetic Subjects |
| January 12 |
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin |
| January 12 |
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191 |
| January 12 |
Seventeen Months After Cord Blood Transplant - Child is Free of Signs of Cancer |
| January 13 |
Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling |
| January 13 |
Hana Biosciences Phase 1 Data On Menadione, Its Novel First-in-Class Compound for Treatment-Limiting Skin Toxicity Associated With EGFR Inhibitors, to be Presented At 33rd Hawaii Dermatology Seminar |
| January 13 |
Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia |
| January 13 |
NeurogesX Announces Publication of Phase 3 Data for QUTENZA (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology |
| January 13 |
AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab Combination (ARX-03) in Treating Procedural Pain and Anxiety |
| January 13 |
InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA |
| January 13 |
Cytos Biotechnology Presents Analysis of Patient Diaries Including Six Month Follow-up Data from Phase II Study with CYT003-QbG10 Monotherapy for the Treatment of Allergic Diseases |
| January 13 |
Nymox Releases Positive New Clinical Trial Data on Durability of Response Rates to Company’s BPH Drug NX-1207 |
| January 13 |
Suven Participates at Biotech Showcase 2009 |
| January 14 |
New Overall Survival Study Results Confirm Oral Xeloda plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer |
| January 14 |
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments |
| January 14 |
New Study First to Confirm Sandostatin LAR Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors |
| January 14 |
Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer |
| January 14 |
Merck KGaA: New Data Reinforce Consistent Efficacy Profile of Erbitux in First-Line mCRC Patients with KRAS Wild-Type Tumors |
| January 14 |
Afinitor Phase II trial results positive in patients with advanced gastric cancer after failure of one or more prior treatments |
| January 14 |
Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer |
| January 14 |
Mologen AG Announces Successful Course of Study of Cancer Drug MGN1703 |
| January 14 |
Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk |
| January 15 |
Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP |
| January 15 |
Pegasys Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine |
| January 15 |
New Tool Could Prevent Needless Stents and Save Money, Stanford Cardiologist Says |
| January 15 |
Study Shows How Defective DNA Repair Triggers Two Neurological Diseases |
| January 15 |
Neurotune Successfully Completes Phase 1 Trials with its Lead Compound NT-11624 |
| January 15 |
A Study In This Month's Journal Of Nervous And Mental Disease Reveals Hope For Recovery From Suicidal Thinking And Treatment Resistant Mental Illness |
| January 16 |
Malaria: New Treatment is Upcoming |
| January 16 |
ediGene: Presentation of Clinical Data Obtained with EndoTAG-1 for the Treatment of Pancreatic Cancer and with the Oncolytic Virus NV1020 for the Treatment of Metastasized Colorectal Carcinoma at the ASCO GI Meeting |
| January 20 |
Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial |
| January 20 |
Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer |
| January 20 |
Unigene Reports Positive Results on a Novel Peptide for Reducing Food Consumption |
| January 20 |
Chemoembolization Improving as Liver Cancer Treatment |
| January 21 |
Aradigm Reports Positive Phase 2 Results with Inhaled Liposomal Ciprofloxacin Hydrochloride in Patients with Bronchiectasis |
| January 21 |
Acusphere Announces Publication of Imagify Phase 3 Trials in the European Journal of Echocardiography |
| January 21 |
Clinuvel: Positive Interim Phase III Results Announced for Unique Skin Protection Drug |
| January 21 |
Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study |
| January 21 |
Measurement of Kidney Function in Children with Kidney Disease Improved |
| January 21 |
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2) |
| January 22 |
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium |
| January 22 |
Zevalin Produced 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma Study |
| January 22 |
DiaKine Therapeutics Drug Improves Type 2 Insulin Action; Reduces Harm of Fat in Preclinical Study |
| January 22 |
Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia |
| January 22 |
Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss |
| January 22 |
New Clinical Equation Accurately Measures Kidney Function in Children |
| January 23 |
Hollis-Eden Researchers Present New Findings on Mechanism of Action for Anti-Cancer Drug Candidate Apoptone (HE3235) |
| January 23 |
Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Phase III Pivotal Trial |
| January 23 |
Promedior's Fibrosis Program Featured at Keystone Symposia Conference |
| January 23 |
VIRxSYS to Present at Phacilitate Cell & Gene Therapy Forum |
| January 23 |
Onconova and DoD Collaborators Publish Research Demonstrating Increased Survivability of Previously Lethal Radiation in Mice with New Radioprotective Drug Ex-RAD |
| January 23 |
Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 |
| January 23 |
Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 |
| January 26 |
University of California San Diego Researchers Present Preclinical Data Demonstrating Benefits of Triolex (HE3286) in Model of Obesity Induced Metabolic Disorders |
| January 26 |
Access Pharmaceuticals Presents New Combination Data on the Company's Angiolix Therapeutic Monoclonal Antibody |
| January 26 |
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing |
| January 27 |
Circulation Publishes Pivotal Two-Year Results On Xience V Drug Eluting Stent |
| January 27 |
Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy |
| January 27 |
EpiCept Announces Positive Results from Phase IIb Trial for EpiCept NP-1 |
| January 27 |
New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease |
| January 28 |
Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Trial |
| January 28 |
St. Jude Finds More Than 100 Gene Variations Linked With Response to Leukemia Treatment |
| January 28 |
Sociability Traced to Particular Region of Brain by Stanford Scientists |
| January 28 |
PolyMedix to Present at Keystone Symposia Global Health Series Tuberculosis Biology, Pathology and Therapy |
| January 28 |
Addex Successfully Completes ADX48621 Phase I Program |
| January 28 |
AMT: Glybera Lowers Pancreatitis Incidence Significantly |
| January 28 |
Support Cells, Not Neurons, Lull the Brain to Sleep |
| January 29 |
New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) |
| January 29 |
Data from Columbia Laboratories' Study for the Prevention of Preterm Birth to be Presented at the Society for Maternal-Fetal Medicine (SMFM) 2009 Annual Meeting |
| January 29 |
CombinatoRx Publishes Data on Selective Amplification of Synergistic Combination Drug Candidate |
| January 29 |
Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain |
| January 29 |
Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief |
| January 29 |
Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment |
| January 30 |
BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis |
| January 30 |
Cymbalta Significantly Reduced Osteoarthritis Knee Pain in New Study |
| January 30 |
ImmuPharma PLC Lupuzor Phase IIb study |
| January 30 |
King Pharmaceuticals Announces Positive Results from a 12-Month Open-Label Safety and Efficacy Study of Embeda Extended Release Capsules |
| January 30 |
Effectiveness of Progesterone in Reducing Preterm Births May Be Altered by Genetic Predisposition |
| January 30 |
Under-Treatment of Pain Exacerbated by Public Perceptions of Medicines and Safety |
| January 30 |
Journal Article Reviews Research Using Oxycyte and PFCs in TBI and Decompression Sickness |
| January 30 |
Cook Medical Unveils the Advance Drug-Eluting Balloon and Other Cutting-Edge Devices to Advance Leg Therapy |
